Clinical Trials on Nyelvi zavarok

Total 2720 results

Bristol-Myers Squibb

Completed

A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US

Melanoma

United States
Ludwig Institute for Cancer Research
Bristol-Myers Squibb; Conquer Cancer Foundation

Completed

Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma

Melanoma

United States
EuMelaReg gGmbH

Active, not recruiting

BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients (Combi-EU)

Melanoma

Germany
Bristol-Myers Squibb

Active, not recruiting

Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy (NICO)

Melanoma

Germany
Bristol-Myers Squibb

Active, not recruiting

A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France (AdjuMel)

Melanoma

France
Bristol-Myers Squibb

Active, not recruiting

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

Melanoma

Australia
University of Colorado, Denver

Completed

SunSmart Intervention in Schools

Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Intratumoral Injections of LL37 for Melanoma

Melanoma

United States
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself (CheckMate204)

Melanoma

United States
Charite University, Berlin, Germany
Max-Planck Institut; Alacris

Completed

Biomarker-driven Therapy for Melanoma (TREAT20plus)

Melanoma
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915)

Melanoma

Belgium, Brazil, United States, Canada, Spain, Greece, France, United Kingdom, Australia, Italy, Austria, Switzerland, Germany, Israel, Russian Federation, Romania, Czechia, Poland, New Zealand
eTheRNA immunotherapies

Terminated

Safety of Intranodal ECI-006 in Melanoma Patients

Melanoma

Belgium, Spain
Hassane M. Zarour, MD
Merck Sharp & Dohme LLC; Melanoma Research Alliance

Completed

Treatment of Advanced Melanoma With MK-3475 and Peginterferon

Melanoma

United States
GlaxoSmithKline

Completed

Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma

Melanoma

France, Belgium
GlaxoSmithKline

Terminated

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

Melanoma

United States, Australia, Spain, Taiwan, Bulgaria, Estonia, Germany, Belgium, France, Sweden, Israel, Poland, Italy, Czechia, Switzerland, Korea, Republic of, Ireland, Canada, Argentina, Netherlands, Russian Federation, Ukraine, Aus... and more
Institut Claudius Regaud

Completed

Optimization of the Patient Care Pathway in Immuno-oncology (OPTIMMUNO)

Melanoma

France
Samsung Medical Center

Withdrawn

Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.

Melanoma
Taizhou Hanzhong biomedical co. LTD

Unknown

A Study of HX008 for the Treatment of Patients With Malignant Melanoma

Melanoma

China
Exact Sciences Corporation

Terminated

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma

Melanoma

United States
Universitair Ziekenhuis Brussel

Active, not recruiting

Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC) (myDCTV)

Melanoma

Belgium
Patrick Ott, MD

Completed

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma

Melanoma

United States
Institut Claudius Regaud

Terminated

Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)

Melanoma

France
Nina Bhardwaj

Terminated

Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)

Melanoma

United States
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Melanoma

United States, France, Italy, United Kingdom, Spain, Belgium, Israel, Mexico, Japan, Canada, Netherlands, Sweden, Korea, Republic of, Australia, Russian Federation, Chile, Germany, Poland, Ireland, New Zealand, Denmark, Switzerland, South Africa
Abramson Cancer Center of the University of Pennsylvania

Completed

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

Melanoma

United States
Bristol-Myers Squibb

Completed

A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine

Melanoma

China
Craig L Slingluff, Jr

Terminated

A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma (Mel62; 6PAC)

Melanoma

United States
Bristol-Myers Squibb

Completed

A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors

Melanoma

China
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)

Melanoma
BioNTech RNA Pharmaceuticals GmbH

Completed

RBL001/RBL002 Phase I Clinical Trial (MERIT)

Melanoma

Austria, Germany
Bristol-Myers Squibb

Active, not recruiting

A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)

Melanoma

United States
Amgen

Completed

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

Melanoma

United States, Canada
Ralph Hauke
Prometheus Laboratories; Nebraska Cancer Specialists; Midwest Cancer Center-Legacy

Terminated

Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma

Melanoma

United States
Yonsei University

Unknown

The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma

Melanoma

Korea, Republic of
SCRI Development Innovations, LLC
GlaxoSmithKline; Celgene

Withdrawn

Study of Trametinib and Nab-paclitaxel in Patients With Melanoma

Melanoma

United States
MedImmune LLC

Completed

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Melanoma

Italy, United States, Canada, France
University Health Network, Toronto

Completed

Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma

Melanoma

Canada
GlaxoSmithKline

Terminated

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Melanoma

Spain, France
Duke University

Withdrawn

A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma

Melanoma

United States
Adaptimmune

Terminated

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

Melanoma

United States
Dartmouth-Hitchcock Medical Center

Completed

Skin Care Behaviors Among Melanoma Survivors and Their Families

Melanoma

United States
Northwestern University
National Institutes of Health (NIH); Vibrent Health

Withdrawn

Teaching Skin Self-Examination to First-degree Relatives of Melanoma Patients Using Mobile App Technology

Melanoma

United States
University of Zurich

Completed

Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel

Melanoma

Switzerland
Bristol-Myers Squibb

Completed

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Melanoma

United States
European Organisation for Research and Treatment...

Withdrawn

SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access

Melanoma
BrightPath Biotherapeutics

Completed

Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma

Melanoma

United States
European Institute of Oncology

Terminated

MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients (MelaViD)

Melanoma

Italy
Diwakar Davar
Bristol-Myers Squibb

Completed

Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma

Melanoma

United States
Moletest Scotland Ltd
NHS Lanarkshire; Digital Health & Care Institute

Completed

Moletest Clinical Study in Scotland

Melanoma

United Kingdom
Genentech, Inc.

Completed

A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma (BEAM)

Melanoma

3

Subscribe